Bill
S 693
S.693 protects prescription drug continuity for medically stable patients and expands Medicaid to cover ovulation‑enhancing (fertility) drugs.
Note on source materials: The documents you provided contain two different and partially conflicting bill texts and procedural histories under the label “S 693.” One text is a Massachusetts-style “non‑medical switching” insurance reform (preserving drug coverage when formularies change). The other is an introduced-version New Jersey bill that would amend Medicaid law to require coverage of ovulation‑enhancing drugs. The procedural history and sponsor list also appear to mix entries from multiple jurisdictions. Below are clear, separate summaries of each version and a short procedural note about the record inconsistencies.
Purpose
- Prevent health carriers from forcing insured patients who are medically stable on a prescription drug to switch to a less costly alternative because of formulary changes made outside clinical judgment (“nonmedical switching”).
Key provisions
- Definitions: establishes terms such as “nonmedical switching,” “covered person,” “formulary,” “discontinued health benefit plan,” and others.
- Prohibition: a health carrier, health plan, or utilization review organization shall not limit or exclude coverage of a prescription drug for any covered person who is medically stable on that drug if:
- The drug was previously approved for that person by the carrier;
- The prescribing clinician prescribed it within the prior six months;
- The person remains enrolled in the plan.
- Examples of prohibited actions: reducing maximum prescription coverage, increasing cost‑sharing, moving a drug to a more restrictive tier, or removing it from the formulary (exceptions for FDA safety advisories or manufacturer discontinuance).
- Continuity: coverage for the drug must continue through the last day of the person’s eligibility, including through open enrollment.
- Coverage exemption process: plans must provide a clear, accessible web‑based process for medical exceptions; carriers must respond to exemption requests within 72 hours (24 hours for exigent circumstances). If no response within the time limit, the exemption is deemed granted. When granted, coverage must be no more restrictive than prior coverage.
Who is affected
- Insured individuals (covered persons) in plans governed by the statute, prescribing clinicians, health carriers and PBM/utilization review organizations; primarily impacts people stabilized on chronic/ongoing prescription therapies.
Potential impacts
- Greater continuity of care and fewer forced switches; potential upward pressure on drug spending for plans that would otherwise substitute lower‑cost alternatives; administrative requirements for carriers.
Purpose
- Amend New Jersey’s Medicaid statute (P.L.1968, c.413) to require coverage of ovulation‑enhancing drugs (fertility medications) as part of medical assistance, consistent with federal Title XIX requirements.
Key provisions (as indicated)
- Modifies Section 6 of P.L.1968, c.413 to explicitly include ovulation‑enhancing drugs among “prescribed drugs”/covered benefits under Medicaid.
- Coverage would be subject to existing federal Medicaid (Title XIX) constraints and state program rules/regulations.
Who is affected
- Medicaid beneficiaries who have infertility or require ovulation‑enhancing drugs; providers who prescribe/dispense these medications; state Medicaid program and budget.
Potential impacts
- Expanded access to fertility treatments for eligible Medicaid enrollees.
- Likely increase in state Medicaid expenditures mitigated in part by federal Medicaid matching funds (Title XIX); fiscal impact depends on scope, utilization, and any limitations or prior authorization rules included in final implementing language.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
